Zynex Inc Stock Price, News & Analysis

Zynex (NASDAQ: ZYXI) announced its uplisting to the Nasdaq Global Select Market, effective July 14, 2021. This achievement highlights Zynex's strong growth and financial performance, meeting stringent financial, liquidity, and governance criteria. CEO Thomas Sandgaard emphasized the importance of this milestone for enhancing shareholder value. The company specializes in non-invasive medical devices for pain management, stroke rehabilitation, and cardiac monitoring. Zynex's proprietary products include electrotherapy devices and blood volume monitors.

Zynex (NASDAQ: ZYXI), a leader in non-invasive medical devices, announced that its CFO, Dan Moorhead, will present virtually at the Ladenburg Thalmann Annual Healthcare Conference on July 13, 2021. The presentation is scheduled from 12:00 PM to 12:25 PM ET, and Moorhead will also engage in one-on-one meetings with investors. Zynex specializes in devices for pain management, stroke rehabilitation, and cardiac monitoring. Further details can be found on the company's website.

Zynex reported a strong Q1 2021 with a 58% increase in revenue to $24.1 million year-over-year. Orders surged by 140%, yet the company faced a net loss of $0.7 million, marking a GAAP loss per share of $0.02. Gross margins were robust at 76%. The CEO anticipates a profitability ramp-up in Q2 with projected Adjusted EBITDA of over $3 million. Guidance for Q2 revenue is estimated between $31 million and $32.5 million, while full-year revenue is expected between $135 million and $150 million.

Zynex, a medical technology firm, has appointed Donald Gregg as the new Vice President of Sales and Operations for its Monitoring Solutions Division. He is tasked with leading the development and marketing of the CM-1500 Blood Volume Monitor, which received FDA clearance in 2020. CEO Thomas Sandgaard expressed confidence in Gregg's ability to enhance product offerings and sales strategies. The division aims to set new standards for detecting internal bleeding. Gregg's extensive background includes roles at Smith Medical and Medtronic, where he achieved significant sales growth.

Zynex, Inc. (Nasdaq: ZYXI) has announced it will host its first quarter earnings investor webcast on April 29, 2021, at 2:15 p.m. MT (4:15 p.m. ET). The company specializes in non-invasive medical devices for pain management and rehabilitation. Participants can register through the provided link or dial in 10-15 minutes prior to the webcast. Founded in 1996, Zynex designs electrotherapy devices and has developed a proprietary NeuroMove device for stroke recovery.

Zynex, Inc. (NASDAQ: ZYXI) reported a remarkable 140% year-over-year order growth for Q1 2021. The company confirmed revenue estimates for the quarter between $23.0 million and $24.5 million, alongside an estimated Adjusted EBITDA loss of $0.5 million to $1.5 million. For the full year 2021, Zynex anticipates revenues between $135.0 million and $150.0 million, marking a 68% to 87% increase from 2020's revenue of $80.1 million. The company is actively expanding its sales team to promote its prescription-strength NexWave device as a safe alternative for pain management.

Zynex, Inc. (NASDAQ: ZYXI) has announced its relocation to a new corporate headquarters in Englewood, Colorado, expanding its space from 86,000 square feet to 110,754 square feet. The new lease, effective May 3, 2021, spans 84 months and includes an option for an additional 56,158 square feet. CEO Thomas Sandgaard highlighted competitive lease rates and significant rent credits that enhance the company's financial position. This move aligns with Zynex's growth in manufacturing and sales of non-invasive medical devices for pain management and rehabilitation.

Zynex, Inc. (NASDAQ: ZYXI) has initiated a $10.0 million share buyback program aimed at enhancing shareholder value. Announced on March 8, 2021, the program will commence immediately and conclude by September 8, 2021, or once the buyback limit is reached. Zynex's leadership, including President and CEO Thomas Sandgaard, expressed confidence in the company's growth prospects and stated that the current market valuation does not reflect its true value. The buybacks will be funded through existing cash and are expected to have no material impact on the company’s capital levels.